<DOC>
	<DOC>NCT01987011</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.</brief_summary>
	<brief_title>Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers</brief_title>
	<detailed_description>MG1109 is purified, inactivated influenza viral antigen.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Healthy adults who are available for followup during the study Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine Subjects with immune system disorder including immune deficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Avian influenza</keyword>
</DOC>